Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 (Oral Stable Form) | Ipamorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. | Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection. |
| Timing | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. | Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach. |
| Cycle Duration | 4-12 weeks. Oral form enables easier long-term use compared to injectable. | 12-24 week cycles with 4-8 week breaks. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as the first selective growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) agonist. Unlike other GHRPs, it selectively stimulates GH release without significantly affecting ACTH, cortisol, prolactin, or aldosterone — even at doses 200-fold above the ED50 for GH release. This selectivity profile is comparable to GHRH itself but operates through the distinct ghrelin receptor on pituitary somatotrophs.
Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection.
Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach.
12-24 week cycles with 4-8 week breaks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →